Trevena, Inc. (TRVN)
USD 1.27
(-0.78%)
USD 1.27
(-0.78%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -40.28 Million USD | 24.93% |
| 2022 | -53.66 Million USD | -4.9% |
| 2021 | -51.16 Million USD | -74.2% |
| 2020 | -29.36 Million USD | -4.68% |
| 2019 | -28.05 Million USD | 8.86% |
| 2018 | -30.78 Million USD | 57.16% |
| 2017 | -71.86 Million USD | 30.22% |
| 2016 | -102.99 Million USD | -103.83% |
| 2015 | -50.52 Million USD | -1.66% |
| 2014 | -49.7 Million USD | -113.75% |
| 2013 | -23.25 Million USD | -48.71% |
| 2012 | -15.63 Million USD | 1.1% |
| 2011 | -15.81 Million USD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.89 Million USD | 36.3% |
| 2024 Q1 | -7.67 Million USD | 53.49% |
| 2023 Q2 | -8.01 Million USD | -34.32% |
| 2023 FY | -40.28 Million USD | 24.93% |
| 2023 Q4 | -16.51 Million USD | -108.2% |
| 2023 Q3 | -7.93 Million USD | 1.02% |
| 2023 Q1 | -5.96 Million USD | 20.06% |
| 2022 Q1 | -16.31 Million USD | -16.95% |
| 2022 FY | -53.66 Million USD | -4.9% |
| 2022 Q4 | -7.46 Million USD | 49.7% |
| 2022 Q3 | -14.83 Million USD | 0.97% |
| 2022 Q2 | -14.98 Million USD | 8.19% |
| 2021 FY | -51.16 Million USD | -74.2% |
| 2021 Q2 | -14.02 Million USD | -42.47% |
| 2021 Q4 | -13.95 Million USD | -1.32% |
| 2021 Q1 | -9.84 Million USD | 17.09% |
| 2021 Q3 | -13.77 Million USD | 1.79% |
| 2020 Q4 | -11.87 Million USD | -113.85% |
| 2020 Q1 | -5.72 Million USD | 11.17% |
| 2020 Q2 | -6.22 Million USD | -8.68% |
| 2020 FY | -29.36 Million USD | -4.68% |
| 2020 Q3 | -5.55 Million USD | 10.78% |
| 2019 Q4 | -6.44 Million USD | 24.76% |
| 2019 Q3 | -8.56 Million USD | -82.6% |
| 2019 Q1 | -5.16 Million USD | 35.19% |
| 2019 Q2 | -4.69 Million USD | 9.25% |
| 2019 FY | -28.05 Million USD | 8.86% |
| 2018 Q1 | -9.02 Million USD | 38.72% |
| 2018 FY | -30.78 Million USD | 57.16% |
| 2018 Q4 | -7.97 Million USD | -77.92% |
| 2018 Q3 | -4.48 Million USD | 51.82% |
| 2018 Q2 | -9.3 Million USD | -3.14% |
| 2017 Q2 | -20.43 Million USD | 1.36% |
| 2017 Q1 | -20.71 Million USD | 42.62% |
| 2017 FY | -71.86 Million USD | 30.22% |
| 2017 Q4 | -14.72 Million USD | 7.99% |
| 2017 Q3 | -15.99 Million USD | 21.7% |
| 2016 Q1 | -17.77 Million USD | -14.97% |
| 2016 Q2 | -19.21 Million USD | -8.08% |
| 2016 FY | -102.99 Million USD | -103.83% |
| 2016 Q4 | -36.1 Million USD | -20.74% |
| 2016 Q3 | -29.89 Million USD | -55.59% |
| 2015 Q3 | -10.61 Million USD | 7.84% |
| 2015 Q1 | -12.92 Million USD | 2.76% |
| 2015 Q2 | -11.51 Million USD | 10.91% |
| 2015 FY | -50.52 Million USD | -1.66% |
| 2015 Q4 | -15.46 Million USD | -45.68% |
| 2014 Q2 | -11.49 Million USD | -22.64% |
| 2014 Q1 | -9.37 Million USD | -35.73% |
| 2014 FY | -49.7 Million USD | -113.75% |
| 2014 Q4 | -13.29 Million USD | 14.41% |
| 2014 Q3 | -15.53 Million USD | -35.14% |
| 2013 Q2 | -4.68 Million USD | -62.33% |
| 2013 Q1 | -2.88 Million USD | 7.4% |
| 2013 Q4 | -6.9 Million USD | 21.37% |
| 2013 FY | -23.25 Million USD | -48.71% |
| 2013 Q3 | -8.78 Million USD | -87.63% |
| 2012 Q4 | -3.11 Million USD | 23.62% |
| 2012 Q3 | -4.07 Million USD | 0.0% |
| 2012 FY | -15.63 Million USD | 1.1% |
| 2011 FY | -15.81 Million USD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| America Great Health | -761.42 Thousand USD | -5191.298% |
| Ampio Pharmaceuticals, Inc. | -8.63 Million USD | -366.74% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | -31.025% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 67.539% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | -150.585% |
| Better Therapeutics, Inc. | -39.76 Million USD | -1.33% |
| Calithera Biosciences, Inc. | -18.86 Million USD | -113.553% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | -119.225% |
| Gene Biotherapeutics, Inc. | - USD | Infinity% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | -12.505% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | -11.712% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 64.821% |
| Evolutionary Genomics, Inc. | -2.24 Million USD | -1692.008% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 46.105% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 31.808% |
| Innovation1 Biotech Inc. | -5.98 Million USD | -572.799% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | -89.204% |
| Molecular Templates, Inc. | -8.12 Million USD | -395.926% |
| Navidea Biopharmaceuticals, Inc. | -15.17 Million USD | -165.458% |
| NexImmune, Inc. | -32.34 Million USD | -24.563% |
| Orgenesis Inc. | -55.36 Million USD | 27.225% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | -59.478% |
| Point of Care Nano-Technology, Inc. | -78.01 Thousand USD | -51541.309% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | -120.282% |
| Scopus BioPharma Inc. | -11.6 Million USD | -247.025% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 92.967% |
| Statera Biopharma, Inc. | -174.4 Million USD | 76.9% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -1022.882% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -70664.394% |
| Vaccinex, Inc. | -20.25 Million USD | -98.948% |
| Vicapsys Life Sciences, Inc. | -1.18 Million USD | -3308.222% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 21.092% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | -418.041% |